# Linezolid

## Zyvox inj 600mg/300mL

| 藥物代碼 | IZYV |
| :--- | :--- |
| 適應症 | Vancomycin-resistant Enterococcus faecium infections, including cases with concurrent bacteremia , Nosocomial pneumonia caused by Staphylococcus aureus ,Complicated skin and skin structure infections caused by Staphylococcus aureus \(methicillin-susceptible and -resistant strains\), Streptococcus pyogenes, or Streptococcus agalactiae |
| 副作用 | diarrhea \(incidence across studies: 2.8-11%\), headache \(incidence across studies: 0.5-11.3%\) and nausea \(incidence across studies: 3.4-9.6%\). |
| 禁忌 | Patients who have known hypersensitivity to linezolid or any of the other components of Zyvox. |
| 藥物保存方式 | N/A |
| 用法用量 | Dosing: dosage adjustment not necessary when switching from intravenous to oral formulation  Adult: Bacteremia associated with intravascular line, Confirmed ampicillin- and vancomycin-resistant Enterococcus faecalis/faecium: \(due to ampicillin- and vancomycin-resistant Enterococcus faecalis/faecium\) 600 mg IV every 12 hours; Community acquired pneumonia: 600 mg IV or ORALLY every 12 hours for 10 to 14 days \(manufacturer dosing\) or for 7 to 21 days when MRSA-associated infection \(guideline dosing\);Infection of bone - Infectious disorder of joint: \(MRSA-associated\) 600 mg IV or ORALLY every 12 hours for a minimum of 8 weeks for osteomyelitis and 3 to 4 weeks for septic arthritis; Infection of skin AND/OR subcutaneous tissue, Complicated: 600 mg IV or ORALLY every 12 hours for 10 to 14 days \(manufacturer dosing\) or for 7 to 14 days when MRSA-associated infection \(guideline dosing\) Pediatric: Community acquired pneumonia: \(12 years and older\) 600 mg IV or ORALLY every 12 hours for 10 to 14 days Community acquired pneumonia: \(birth through 11 years of age\) 10 mg/kg IV or ORALLY every 8 hours for 10 to 14 days, not to exceed 600 mg/dose Community acquired pneumonia: \(preterm neonates less than 34 weeks gestation\) 10 mg/kg IV or ORALLY every 12 hours, increase to 10 mg/kg IV or ORALLY every 8 hours by 7 days of life or sooner for suboptimal clinical response; recommended duration of treatment, 10 to 14 days **\***NEONATE ANTIBIOTICS DOSE**\*** Linezolid: Oral, IV. Bacteremia, community/ hospital-acquired pneumonia, skin infections. Vancomycin-resistant Enterococcus faecium \(VREF\) infection GA &lt;34 week Postnatal 0-7 days, dose: 10mg/kg Q12H GA =8 days, dose: 10mg/kg Q8H GA 33-44 week Postnatal 0-28 days, dose: 10mg/kg Q8H |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | Linezolid和代謝物會分泌至授乳大鼠的乳汁 |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【D5W】 可選  【L/R】 可選  【N/S】 可選 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | 輸注時間建議以30至120分鐘 |
| 注意事項 | 1. 靜脈投與Zyvox Inj. 時，輸注時間應為30至120分鐘。不得使用此靜脈輸注袋作一系列的聯結。添加物不得注入此輸注液中。當使用ZYVOX靜脈注射劑必須同時併用其他藥物時，應該根據每一個藥品的建議劑量和投與途徑分開投與。 2. Zyvox Inj.應避光儲存於25°C以下。瓶口應緊閉以避免潮濕。輸注袋在使用前，建議應保存在鋁箔外包裝內。輸注袋應預防結冰。藥物在投與之前應用眼睛檢查是否有微粒存在。 3. 注意副作用：乳酸性酸中毒、血清素症候群\(併用血清素類製劑或酪胺酸食品\)、週邊神經病變及視神經病變、痙攣。 |

## Zyvox 600mg

| 藥物代碼 | OZYV |
| :--- | :--- |
| 適應症 | Vancomycin-resistant Enterococcus faecium infections, including cases with concurrent bacteremia , Nosocomial pneumonia caused by Staphylococcus aureus ,Complicated skin and skin structure infections caused by Staphylococcus aureus \(methicillin-susceptible and -resistant strains\), Streptococcus pyogenes, or Streptococcus agalactiae |
| 副作用 | diarrhea \(incidence across studies: 2.8-11%\), headache \(incidence across studies: 0.5-11.3%\) and nausea \(incidence across studies: 3.4-9.6%\). |
| 禁忌 | Patients who have known hypersensitivity to linezolid or any of the other components of Zyvox. |
| 藥物保存方式 | N/A |
| 用法用量 | May be taken with or without food MRSA: 600 mg 12 hr daily 10-14 days Vancomycin-resistant Enterococcus faecium inf. 600 mg IV or orally every 12 hr for 14-28 days. Nosocomial & community-acquired pneumonia, complicated skin & skin structure infection: 600 mg IV or orally every 12 hr for 10-14 days. Uncomplicated skin & skin structure infection: 400 mg orally every 12 hr for 10-14 days. Premature or neonate &lt; 7 days 10 mg/kg/dose 12 hrly. Premature or neonate &gt; 7 days-11 year 10 mg/kg/dose 8 hrly. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

